The Role of Methylene Blue in the Pediatric Patient With Vasoplegic Syndrome

Tarun Bhalla*, Amod Sawardekar, Hyde Russell, Joseph D. Tobias

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Patients with vasoplegic syndrome (VPS) in the post-cardiopulmonary bypass setting usually require escalating vasopressor support. The utilization of methylene blue (MB) in the treatment of VPS in the adult population has been well described. We present a 5-year-old girl who developed vasodilatory shock due to VPS that was resistant to escalating doses of adrenergic agonists following cardiac transplantation. After receiving 1 mg/kg of MB, there was a significant improvement in the patient’s mean arterial pressure which allowed for progressive weaning of the vasopressor support. To date, there are limited data regarding the use of MB in pediatric patients with VPS following cardiothoracic surgery. The cellular mechanisms of MB in VPS are discussed and reports of its use in the adult and pediatric population are reviewed. Dosing regimens and potential adverse effects of MB are presented.

Original languageEnglish (US)
Pages (from-to)652-655
Number of pages4
JournalWorld Journal for Pediatric and Congenital Heart Surgery
Issue number4
StatePublished - Oct 2011


  • anesthesia (includes agents
  • care and research)
  • congenital heart surgery
  • heart
  • organ or cell)
  • pharmacology
  • pharmacology (combine with target disease
  • transplantation
  • vascular tone and reactivity

ASJC Scopus subject areas

  • Surgery
  • Pediatrics, Perinatology, and Child Health
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The Role of Methylene Blue in the Pediatric Patient With Vasoplegic Syndrome'. Together they form a unique fingerprint.

Cite this